Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Biodetection

    Far Too Few Rapid COVID-19 Tests Available in U.S. to Put a Dent in the Pandemic

    By Bonnie LaFleur and Katherine EllingsonDecember 1, 2020
    Credit: LCP Natalie Greenwood
    Share
    Facebook LinkedIn Reddit Email

    Since September, the Food and Drug Administration has approved seven COVID-19 tests that yield results in 30 minutes or less, offering hope for vast improvements in test access and efficiency throughout the U.S. Most of these are antigen tests that look for viral proteins and can be processed on portable machines or cards.

    The idea behind these rapid tests is to detect symptomatic, pre-symptomatic and asymptomatic infectious people before they can spread the coronavirus. But despite massive distribution of these tests by federal officials – including to date over 40 million of 150 million rapid tests ordered from the medical company Abbott – COVID-19 transmission has been surging in every state since early November.

    This calls into question whether the current influx of rapid tests can actually slow the spread of COVID-19.

    In some targeted applications – and if people take other precautions including mask wearing and social distancing – rapid tests can be a valuable tool. But the current state of availability and accuracy of these tests greatly limit how effective they are at slowing the spread of the virus in communities.

    A healthcare worker placing a sample into a the small Abbott ID Now processing machine.
    Rapid tests like the Abbott ID Now require only small, portable machines and can give results in 15 minutes, but they sacrifice accuracy. AP Photo/Jeff Chiu

    Speed Over Accuracy

    Rapid antigen tests are an attractive option because in addition to their speed, they are cheap and easy to produce and therefore more broadly available than the more commonly used gold-standard PCR tests in theory. But these attributes come with a trade-off: less diagnostic accuracy. This makes them an excellent candidate for use as a screening tool, though less useful for accurately diagnosing SARS-CoV-2 infection.

    One-time testing does not mean that a person can safely travel or mingle without precautions. And while no test is perfectly accurate, there are real questions about the performance of the new rapid tests.

    A few test manufacturers reported accuracy between 84.0% and 97.6% in individuals who are tested within five days after developing COVID-19 symptoms. There is, however, an apparent gap between the reported performance of these tests and what is achieved in the real world. Anecdotally, these tests seem to miss recent, mild and asymptomatic infections – in fact, rapid tests are authorized by the U.S. Centers for Disease Control and Prevention only for use in symptomatic COVID-19 patients. And of course, people can still be infected soon after getting tested.

    For rapid tests to effectively limit spread of the coronavirus, experts suggest that they must be conducted with high frequency – you might miss some cases, but if everyone were getting tested all the time, you would catch a lot of cases too. But even frequent testing is not a panacea. It’s only one part of an approach that must also include social distancing, mask wearing and other precautions.

    A highly publicized example of how a rapid testing strategy can go wrong occurred when President Trump and many in his inner circle contracted COVID-19, likely stemming from a single superspreading event. Everyone was reportedly getting daily rapid tests, but they were largely ignoring other measures like face masks and social distancing. It is likely that someone was infected and asymptomatic, tested negative, and then started the outbreak.

    Widespread, Repeat Testing

    Detecting pre-symptomatic and asymptomatic individuals who are infectious is critical to controlling the coronavirus. Rapid tests can do this, but only if people are screened repeatedly on a schedule – much as what has been happening in some professional and intercollegiate sports.

    The idea is that by testing people early and often – perhaps even as much as every day – rapid tests can catch infected people before they spread the coronavirus to others. But on a national scale, that is a huge number of tests.

    Researchers have estimated that the U.S. would need to perform at least 20 million rapid tests per day to drive down infections. The 150 million rapid tests ordered by the government in late August were earmarked for high-risk populations, but would barely cover one week for the population at large. And don’t forget that logistic capabilities, compliance to frequent testing and the infrastructure to act quickly on results all need to happen as well.

    A healthcare worker administering a rapid test to an elderly man.
    Nursing homes were some of the first places to receive rapid tests. AP Photo/Ted S. Warren

    A Targeted Approach

    There simply aren’t enough rapid tests being produced for the general public to get repeat testing, so the federal government has prioritized deployment of rapid tests to the high-risk population of nursing homes. Federal guidelines for rapid test use in long-term care facilities are a great example of what a testing program might look like – but also illustrate the current challenges in the use of rapid tests.

    If even one person in a nursing home tests positive, all staff and residents must be tested every three to seven days until the facility has been free of COVID–19 for 14 days. When a facility has no cases, all staff are required to get tested according to their county’s test-positivity rate – the higher the rate, the more testing is needed.

    Yet nursing homes have had problems with accuracy, staffing and costs while using these tests and find themselves again in crisis during the current surge. While the rapid tests certainly helped catch many cases and should be used in these settings, they cannot single-handedly overcome larger issues that contribute to spread in these settings.

    Rapid tests can be effective in highly controlled settings where people are tested frequently and other mitigation measures are in place. Look to the success of the NBA bubble as proof. But in other settings where isolation, mask wearing and social distancing are hard to implement or not followed – like nursing homes or the White House – rapid tests have not kept the virus at bay.

    Current testing capacity is nowhere near the hundreds of millions of tests per week required to protect the general population. To date, the promise of cheap and convenient COVID-19 tests being the sole means of controlling disease transmission has not been realized.

    ABOUT THE AUTHORS

    Bonnie LaFleur, PhD, is a Research Professor of Biostatistics at The University of Arizona’s BIO5 Institute. Dr. LaFleur’s scientific biography reflects her 25-year career as both a collaborative statistician and a scientific leader in precision medicine using genomic and clinical biomarkers. She is an accomplished quantitative scientist with exceptional blend of scientific research, experiment development and execution, technical, statistical and data analysis capabilities. In addition to her years in the academic sector, she is a recognized industry leader and subject matter expert in the areas of bioinformatics and biostatistics; including predictive modeling, tools for visualization, scientific writing, and public speaking. She holds three patents and has worked on four successful FDA device clearances.

    Katherine Ellingson, PhD is an Assistant Professor of Epidemiology and Biostatistics, University of Arizona. Ellingson joined the College of Public Health in 2017 following 10 years of public service as a healthcare epidemiologist at the Centers for Disease Control and Prevention (CDC) and the Oregon State Health Department. While at CDC, she investigated the transmission of multidrug-resistant organisms in healthcare settings, evaluated initiatives to prevent healthcare-associated infections, built capacity for infection prevention in resource-limited settings, and served as the agency’s subject matter expert for hand hygiene in healthcare. At the Oregon Health Department, she directed the state’s mandatory healthcare-associated infection reporting program, investigated infectious disease outbreaks and led injection safety promotion efforts.

    This article is courtesy of The Conversation.

    COVID-19 Editor Pick Nonpharmaceutical Interventions POC Diagnostics Rapid Diagnostics SARS-CoV-2
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleOxford-AstraZeneca COVID-19 Vaccine: Cheaper and Doesn’t Require Supercold Storage Quagmire
    Next Article OHDSI Awarded $10M FDA Contract to Monitor Safety and Effectiveness of Vaccines, Biologics

    Related Stories

    EPA Developing AMR Risk Framework for Antibacterial and Antifungal Pesticides

    September 29, 2023

    Provide Feedback on Federal DURC Biosafety Oversight of Potential Pandemic Pathogens

    September 24, 2023

    Committee to Examine Transmission and Geographic Spread of Chronic Wasting Disease

    September 24, 2023

    New Method Improves Quantification of Ricin in Complex Matrices

    September 20, 2023
    News Scan

    Biodefense Headlines – 19 September 2023

    News Scan September 19, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include a global survey of gain-of-function research; funding of an mRNA mpox vaccine; Nipah virus outbreak in India; field detection of threat agents with acoustic…

    Upcoming Events

    Oct 3
    Virtual Event Virtual Event
    October 3 - October 5

    OneLab Summit 2023

    Oct 3
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships to Distribute, Dispense, and Administer Medical Countermeasures

    Oct 4
    Virtual Event Virtual Event
    10:00 am - 2:00 pm EDT

    Tunneling Nanotubes and Intracellular Protrusions Workshop

    Oct 12
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships for Acceptance and Uptake of Medical Countermeasures

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.

    We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy